Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PAVmed (PAVM) Net Income towards Common Stockholders (2016 - 2025)

PAVmed has reported Net Income towards Common Stockholders over the past 5 years, most recently at -$1.8 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders fell 236.11% year-over-year to -$1.8 million; the TTM value through Dec 2025 reached -$3.8 million, up 88.34%, while the annual FY2025 figure was -$3.8 million, 111.81% down from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was -$1.8 million at PAVmed, up from -$6.3 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $17.7 million in Q1 2025 and troughed at -$26.2 million in Q3 2022.
  • A 5-year average of -$12.8 million and a median of -$14.6 million in 2023 define the central range for Net Income towards Common Stockholders.
  • On a YoY basis, Net Income towards Common Stockholders climbed as much as 177.65% in 2025 and fell as far as 236.11% in 2025.
  • Year by year, Net Income towards Common Stockholders stood at -$17.3 million in 2021, then decreased by 18.79% to -$20.5 million in 2022, then rose by 22.54% to -$15.9 million in 2023, then soared by 108.46% to $1.3 million in 2024, then tumbled by 236.11% to -$1.8 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for PAVM at -$1.8 million in Q4 2025, -$6.3 million in Q3 2025, and -$13.3 million in Q2 2025.